Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $6.25

GoodRx (NASDAQ:GDRX) had its price target dropped by equities researchers at Citigroup from $7.00 to $6.25 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 37.36% from the company’s current price.

GDRX has been the subject of a number of other research reports. Morgan Stanley lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Barclays lowered their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. KeyCorp lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Mizuho started coverage on shares of GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, GoodRx has a consensus rating of “Moderate Buy” and an average target price of $8.38.

GoodRx Stock Performance

NASDAQ:GDRX opened at $4.55 on Friday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $1.73 billion, a P/E ratio of -151.67, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27. The firm has a 50 day moving average of $4.72 and a 200-day moving average of $6.56. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new stake in GoodRx in the second quarter valued at approximately $18,183,000. Point72 Asset Management L.P. acquired a new position in shares of GoodRx during the third quarter worth $11,295,000. Rubric Capital Management LP lifted its holdings in shares of GoodRx by 76.5% during the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after purchasing an additional 1,619,748 shares during the period. Millennium Management LLC lifted its holdings in shares of GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after purchasing an additional 1,102,758 shares during the period. Finally, Franklin Resources Inc. acquired a new position in shares of GoodRx during the third quarter worth $5,675,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.